





Psoriasis and Race/Ethnic Variations

PSOLAR: Prospective Registry of Patients With Moderate-to-Severe PsO – A North American Dataset

Prevalence of PsO Comorbidities by Self-Reported Race/Ethnicity¹




Association of Self-Reported Race/Ethnicity With HRQoL¹



Patients with moderate-to-severe PsO who are black have **higher rates of obesity and CVD than white patients** and are more likely to have a **poorer QoL** due to the impact of disease¹

80% of black patients reported a DLQI of ≥2, vs. 69% of white patients¹




Presentation of PsO in Patients With Skin of Color

In individuals with darker skin types, **recognizing inflammation** is nuanced since erythema often appears violaceous, dark brown, or gray²



Post-inflammatory hyperpigmentation secondary to PsO³

Patients may be left with **hyper- or hypopigmentation** after psoriatic lesions have resolved²



PsO in an African American woman³

Prevalence of PsO varies between different races⁴

Race and ethnicity may be associated with socioeconomic disparities that impact **access and adherence** to different types of treatments⁵



Explore the other infographics in the **Comorbidities in Psoriasis** series

BMI=body mass index; CVD=cardiovascular disease; DLQI=dermatology life quality index; HRQoL=health-related quality of life; PsO=psoriasis; PSOLAR=psoriasis longitudinal assessment and registry; QoL=quality of life.
1. Takeshita J, et al. *J Invest Dermatol.* 2022;142(9):2528-2531.e3. 2. Kaufman BP, Alexis AF. *Am J Clin Dermatol.* 2018;19(3):405-423. 3. Alexis AF, Blackcloud P. *J Clin Aesthet Dermatol.* 2014;7(11):16-24. 4. Armstrong AW, et al. *JAMA Dermatol.* 2021;157(8):940-946. 5. Xie Z, et al. *PLoS One.* 2019;14(2):e0212117.